DDInter1628 DDInter1949
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels. Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition to 20 million others worldwide. It was developed by Global Blood Therapeutics, Inc. and is unique from other drugs used to treat sickle cell anemia, such as [hydroxyurea], [L-glutamine], and [crizanlizumab][A188135,A188138] due to its novel mechanism of action. The EMA approved the use of voxelotor for the treatment of hemolytic anemia associated with sickle cell disease in February 2022.[L41419,L41424]
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Weight increased
Weight increased {u} (Side Effect) is caused by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Hypercholesterolaemia
Hypercholesterolaemia {u} (Side Effect) is caused by {v} (Compound) Fluconazole
Fluconazole {u} may lead to a major life threatening interaction when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) downregulates {v} (Gene) BNIP3
BNIP3 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib {u} (Compound) downregulates {v} (Gene) BNIP3
BNIP3 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Voxelotor
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Ruxolitinib (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Voxelotor
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) causes Weight increased (Side Effect) and Weight increased (Side Effect) is caused by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) causes Hypercholesterolaemia (Side Effect) and Hypercholesterolaemia (Side Effect) is caused by Fluconazole (Compound) and Fluconazole may lead to a major life threatening interaction when taken with Voxelotor
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) downregulates BNIP3 (Gene) and BNIP3 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Ruxolitinib (Compound) downregulates BNIP3 (Gene) and BNIP3 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor